Health
Anakinra shows therapeutic potential in critically ill COVID-19 patients – News-Medical.Net
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill COVID-19…
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill coronavirus disease 2019 (COVID-19) patients. Their findings suggest that treatment with an interleukin-1 (IL-1) receptor antagonist, anakinra, can improve the clinical output of severe COVID-19 patients. The study is currently available on the medRxiv* preprint server.
Background
Since the emergence of the COVID-19 pandemic caused by severe…
-
Noosa News15 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General22 hours agoMinecraft mayhem: ‘Chicken jockey’ chaos reaches Australian cinemas
-
General16 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
Noosa News18 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate